2CL Stock Overview
A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
BridgeBio Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$25.17 |
52 Week High | US$38.91 |
52 Week Low | US$15.75 |
Beta | 1.08 |
11 Month Change | -1.10% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | -52.95% |
5 Year Change | 5.65% |
Change since IPO | 1.70% |
Recent News & Updates
Recent updates
Shareholder Returns
2CL | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -0.9% | 0.6% |
1Y | n/a | -18.0% | 3.3% |
Return vs Industry: Insufficient data to determine how 2CL performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2CL performed against the German Market.
Price Volatility
2CL volatility | |
---|---|
2CL Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2CL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2CL's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 553 | Neil Kumar | bridgebio.com |
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
BridgeBio Pharma, Inc. Fundamentals Summary
2CL fundamental statistics | |
---|---|
Market cap | €4.33b |
Earnings (TTM) | -€498.48m |
Revenue (TTM) | €202.44m |
21.4x
P/S Ratio-8.7x
P/E RatioIs 2CL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2CL income statement (TTM) | |
---|---|
Revenue | US$218.60m |
Cost of Revenue | US$2.39m |
Gross Profit | US$216.20m |
Other Expenses | US$754.47m |
Earnings | -US$538.26m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.88 |
Gross Margin | 98.91% |
Net Profit Margin | -246.23% |
Debt/Equity Ratio | -165.5% |
How did 2CL perform over the long term?
See historical performance and comparison